English

ReAble Therapeutics, Inc.

EDGAR

Quarterly report (10-Q) · filed 2006-11-09

54 filing records in this dataset, filed from 1996-05-15 to 2006-11-09. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

92.9 million USD

2006-09-30 · USD

Exact inputs and evidence

Revenue: 92911000 USD Source

Operating margin

11.36%

2006-09-30 · %

Exact inputs and evidence

Operating Income: 10557000 USD Source
Revenue: 92911000 USD Source

Cash and cash equivalents: 32.1 million USD 2006-09-30 Source
Exact value

32123000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2006-11-09.

Financial data available through: 2005-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2005-12-31
Operating income: 11 of 11 periods available· newest 2005-12-31
Net income: 11 of 11 periods available· newest 2005-12-31
Operating cash flow: 11 of 11 periods available· newest 2005-12-31
Capital expenditure: 11 of 11 periods available· newest 2005-12-31
Total assets: 9 of 11 periods available· newest 2005-12-31
Total liabilities: 9 of 11 periods available· newest 2005-12-31
Current assets: 9 of 11 periods available· newest 2005-12-31
Current liabilities: 9 of 11 periods available· newest 2005-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2005-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+98.4%

Prior period

USD 148.08 million

2004-01-01 – 2004-12-31
Current period

USD 293.73 million

2005-01-01 – 2005-12-31

Exact inputs and evidence

293726000 − 148081000 = 145645000 USD

148081000 USD · 2004-01-01 – 2004-12-31
Inspect prior input Prior source
293726000 USD · 2005-01-01 – 2005-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ReAble Therapeutics, Inc. · 2005-12-31 ReAble Therapeutics, Inc. (edgar:944763) Year-over-year change in Revenue: 145645000 USD Concept: fundies:Revenue Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 293726000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#9131 Input fundies:Revenue: 148081000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#9131
The citation records this snapshot. The page link may show a newer release later.
Net income
+123.1%

Prior period

USD 5.53 million

2004-01-01 – 2004-12-31
Current period

USD 12.33 million

2005-01-01 – 2005-12-31

Exact inputs and evidence

12330000 − 5527000 = 6803000 USD

5527000 USD · 2004-01-01 – 2004-12-31
Inspect prior input Prior source
12330000 USD · 2005-01-01 – 2005-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ReAble Therapeutics, Inc. · 2005-12-31 ReAble Therapeutics, Inc. (edgar:944763) Year-over-year change in Net income: 6803000 USD Concept: fundies:NetIncome Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 12330000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12102 Input fundies:NetIncome: 5527000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12102
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+6,553.1%

Prior period

USD 294,000

2004-01-01 – 2004-12-31
Current period

USD 19.56 million

2005-01-01 – 2005-12-31

Exact inputs and evidence

19560000 − 294000 = 19266000 USD

294000 USD · 2004-01-01 – 2004-12-31
Inspect prior input Prior source
19560000 USD · 2005-01-01 – 2005-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ReAble Therapeutics, Inc. · 2005-12-31 ReAble Therapeutics, Inc. (edgar:944763) Year-over-year change in Operating cash flow: 19266000 USD Concept: fundies:OperatingCashFlow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 19560000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12414 Input fundies:OperatingCashFlow: 294000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12414
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+39.3%

Prior period

USD 5.75 million

2004-01-01 – 2004-12-31
Current period

USD 8.01 million

2005-01-01 – 2005-12-31

Exact inputs and evidence

8010000 − 5752000 = 2258000 USD

5752000 USD · 2004-01-01 – 2004-12-31
Inspect prior input Prior source
8010000 USD · 2005-01-01 – 2005-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ReAble Therapeutics, Inc. · 2005-12-31 ReAble Therapeutics, Inc. (edgar:944763) Year-over-year change in Capital expenditure: 2258000 USD Concept: fundies:CapitalExpenditure Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 8010000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12489 Input fundies:CapitalExpenditure: 5752000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12489
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2005 2005-01-01 – 2005-12-31

Revenue USD 293.73 million 100% of revenue
Cost of revenue USD 114.78 million 39% of revenue
Operating expenses USD 135.26 million 46% of revenue
Operating income USD 43.69 million 15% of revenue
Tax, interest and other Derived USD 31.36 million 11% of revenue
Net income USD 12.33 million 4.2% of revenue

Cash

Operating cash flow USD 19.56 million 6.7% of revenue
Capital expenditure USD 8.01 million 2.7% of revenue
Free cash flow Derived USD 11.55 million 3.9% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

1999 88%
2000 Operating loss: operating costs were 114% of revenue.
2001 96%
2001 96%
2002 93%
2002 93%
2003 Net loss: net income was −2.3% of revenue.
2003 Net loss: net income was −2.7% of revenue.
2004 90%
2005 11%85%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
1999 1999-01-01 – 1999-12-31	26095000	23080000 Derived	3015000	1396000 Derived	1619000	-1152000 Derived	Source 1999-01-01 – 1999-12-31: 26095000 USD Inspect Revenue Open source 1999-01-01 – 1999-12-31: 3015000 USD Inspect Operating Income Open source 1999-01-01 – 1999-12-31: 1619000 USD Inspect Net Income Open source 1999-01-01 – 1999-12-31: 951000 USD Inspect Operating Cash Flow Open source 1999-01-01 – 1999-12-31: 2103000 USD Inspect Capital Expenditure Open source
2000 2000-01-01 – 2000-12-31	30028000	34122000 Derived	-4094000	-831000 Derived	-3263000	-4627000 Derived	Source 2000-01-01 – 2000-12-31: 30028000 USD Inspect Revenue Open source 2000-01-01 – 2000-12-31: -4094000 USD Inspect Operating Income Open source 2000-01-01 – 2000-12-31: -3263000 USD Inspect Net Income Open source 2000-01-01 – 2000-12-31: -2933000 USD Inspect Operating Cash Flow Open source 2000-01-01 – 2000-12-31: 1694000 USD Inspect Capital Expenditure Open source
2001 2000-12-11 – 2001-12-10	42616000	41072000 Derived	1544000	996000 Derived	548000	6118000 Derived	Source 2000-12-11 – 2001-12-10: 42616000 USD Inspect Revenue Open source 2000-12-11 – 2001-12-10: 1544000 USD Inspect Operating Income Open source 2000-12-11 – 2001-12-10: 548000 USD Inspect Net Income Open source 2000-12-11 – 2001-12-10: 8823000 USD Inspect Operating Cash Flow Open source 2000-12-11 – 2001-12-10: 2705000 USD Inspect Capital Expenditure Open source
2001 2001-01-01 – 2001-12-31	42616000	41072000 Derived	1544000	996000 Derived	548000	6118000 Derived	Source 2001-01-01 – 2001-12-31: 42616000 USD Inspect Revenue Open source 2001-01-01 – 2001-12-31: 1544000 USD Inspect Operating Income Open source 2001-01-01 – 2001-12-31: 548000 USD Inspect Net Income Open source 2001-01-01 – 2001-12-31: 8823000 USD Inspect Operating Cash Flow Open source 2001-01-01 – 2001-12-31: 2705000 USD Inspect Capital Expenditure Open source
2002 2001-12-11 – 2002-12-10	95491000	88398000 Derived	7093000	7087000 Derived	6000	8110000 Derived	Source 2001-12-11 – 2002-12-10: 95491000 USD Inspect Revenue Open source 2001-12-11 – 2002-12-10: 7093000 USD Inspect Operating Income Open source 2001-12-11 – 2002-12-10: 6000 USD Inspect Net Income Open source 2001-12-11 – 2002-12-10: 9604000 USD Inspect Operating Cash Flow Open source 2001-12-11 – 2002-12-10: 1494000 USD Inspect Capital Expenditure Open source
2002 2002-01-01 – 2002-12-31	95491000	88398000 Derived	7093000	7087000 Derived	6000	8110000 Derived	Source 2002-01-01 – 2002-12-31: 95491000 USD Inspect Revenue Open source 2002-01-01 – 2002-12-31: 7093000 USD Inspect Operating Income Open source 2002-01-01 – 2002-12-31: 6000 USD Inspect Net Income Open source 2002-01-01 – 2002-12-31: 9604000 USD Inspect Operating Cash Flow Open source 2002-01-01 – 2002-12-31: 1494000 USD Inspect Capital Expenditure Open source
2003 2002-12-11 – 2003-12-10	108059000	98844000 Derived	9215000	11732000 Derived	-2517000	8077000 Derived	Source 2002-12-11 – 2003-12-10: 108059000 USD Inspect Revenue Open source 2002-12-11 – 2003-12-10: 9215000 USD Inspect Operating Income Open source 2002-12-11 – 2003-12-10: -2517000 USD Inspect Net Income Open source 2002-12-11 – 2003-12-10: 10929000 USD Inspect Operating Cash Flow Open source 2002-12-11 – 2003-12-10: 2852000 USD Inspect Capital Expenditure Open source
2003 2003-01-01 – 2003-12-31	93029000	83085000 Derived	9944000	12461000 Derived	-2517000	8102000 Derived	Source 2003-01-01 – 2003-12-31: 93029000 USD Inspect Revenue Open source 2003-01-01 – 2003-12-31: 9944000 USD Inspect Operating Income Open source 2003-01-01 – 2003-12-31: -2517000 USD Inspect Net Income Open source 2003-01-01 – 2003-12-31: 10929000 USD Inspect Operating Cash Flow Open source 2003-01-01 – 2003-12-31: 2827000 USD Inspect Capital Expenditure Open source
2004 2004-01-01 – 2004-12-31	148081000	133514000 Derived	14567000	9040000 Derived	5527000	-5458000 Derived	Source 2004-01-01 – 2004-12-31: 148081000 USD Inspect Revenue Open source 2004-01-01 – 2004-12-31: 14567000 USD Inspect Operating Income Open source 2004-01-01 – 2004-12-31: 5527000 USD Inspect Net Income Open source 2004-01-01 – 2004-12-31: 294000 USD Inspect Operating Cash Flow Open source 2004-01-01 – 2004-12-31: 5752000 USD Inspect Capital Expenditure Open source
2005 2005-01-01 – 2005-12-31	293726000	250039000 Derived	43687000	31357000 Derived	12330000	11550000 Derived	Source 2005-01-01 – 2005-12-31: 293726000 USD Inspect Revenue Open source 2005-01-01 – 2005-12-31: 43687000 USD Inspect Operating Income Open source 2005-01-01 – 2005-12-31: 12330000 USD Inspect Net Income Open source 2005-01-01 – 2005-12-31: 19560000 USD Inspect Operating Cash Flow Open source 2005-01-01 – 2005-12-31: 8010000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 293.7M 2005

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
19991999-12-31	Revenue	26095000	Revenue: 26095000 Open source
20002000-12-31	Revenue	30028000	Revenue: 30028000 Open source
20012001-12-10	Revenue	42616000	Revenue: 42616000 Open source
20012001-12-31	Revenue	42616000	Revenue: 42616000 Open source
20022002-12-10	Revenue	95491000	Revenue: 95491000 Open source
20022002-12-31	Revenue	95491000	Revenue: 95491000 Open source
20032003-12-10	Revenue	108059000	Revenue: 108059000 Open source
20032003-12-31	Revenue	93029000	Revenue: 93029000 Open source
20042004-12-31	Revenue	148081000	Revenue: 148081000 Open source
20052005-12-31	Revenue	293726000	Revenue: 293726000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

98.4% 2005

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
19991999-12-31	Year over year	-10%	Revenue: 26095000 Open source Revenue: 28990000 Open source
20002000-12-31	Year over year	15.1%	Revenue: 30028000 Open source Revenue: 26095000 Open source
20012001-12-10	Year over year	No prior comparable period	Revenue: 42616000 Open source
20012001-12-31	Year over year	41.9%	Revenue: 42616000 Open source Revenue: 30028000 Open source
20022002-12-10	Year over year	124.1%	Revenue: 95491000 Open source Revenue: 42616000 Open source
20022002-12-31	Year over year	124.1%	Revenue: 95491000 Open source Revenue: 42616000 Open source
20032003-12-10	Year over year	13.2%	Revenue: 108059000 Open source Revenue: 95491000 Open source
20032003-12-31	Year over year	-2.6%	Revenue: 93029000 Open source Revenue: 95491000 Open source
20042004-12-31	Year over year	59.2%	Revenue: 148081000 Open source Revenue: 93029000 Open source
20052005-12-31	Year over year	98.4%	Revenue: 293726000 Open source Revenue: 148081000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 14.9% 2005

Net margin 4.2% 2005

Free cash flow margin 3.9% 2005

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
19991999-12-31	Operating margin	11.6%	Operating Income: 3015000 Open source Revenue: 26095000 Open source
20002000-12-31	Operating margin	-13.6%	Operating Income: -4094000 Open source Revenue: 30028000 Open source
20012001-12-10	Operating margin	3.6%	Operating Income: 1544000 Open source Revenue: 42616000 Open source
20012001-12-31	Operating margin	3.6%	Operating Income: 1544000 Open source Revenue: 42616000 Open source
20022002-12-10	Operating margin	7.4%	Operating Income: 7093000 Open source Revenue: 95491000 Open source
20022002-12-31	Operating margin	7.4%	Operating Income: 7093000 Open source Revenue: 95491000 Open source
20032003-12-10	Operating margin	8.5%	Operating Income: 9215000 Open source Revenue: 108059000 Open source
20032003-12-31	Operating margin	10.7%	Operating Income: 9944000 Open source Revenue: 93029000 Open source
20042004-12-31	Operating margin	9.8%	Operating Income: 14567000 Open source Revenue: 148081000 Open source
20052005-12-31	Operating margin	14.9%	Operating Income: 43687000 Open source Revenue: 293726000 Open source
19991999-12-31	Net margin	6.2%	Net Income: 1619000 Open source Revenue: 26095000 Open source
20002000-12-31	Net margin	-10.9%	Net Income: -3263000 Open source Revenue: 30028000 Open source
20012001-12-10	Net margin	1.3%	Net Income: 548000 Open source Revenue: 42616000 Open source
20012001-12-31	Net margin	1.3%	Net Income: 548000 Open source Revenue: 42616000 Open source
20022002-12-10	Net margin	0%	Net Income: 6000 Open source Revenue: 95491000 Open source
20022002-12-31	Net margin	0%	Net Income: 6000 Open source Revenue: 95491000 Open source
20032003-12-10	Net margin	-2.3%	Net Income: -2517000 Open source Revenue: 108059000 Open source
20032003-12-31	Net margin	-2.7%	Net Income: -2517000 Open source Revenue: 93029000 Open source
20042004-12-31	Net margin	3.7%	Net Income: 5527000 Open source Revenue: 148081000 Open source
20052005-12-31	Net margin	4.2%	Net Income: 12330000 Open source Revenue: 293726000 Open source
19991999-12-31	Free cash flow margin	-4.4%	Revenue: 26095000 Open source Operating Cash Flow: 951000 Open source Capital Expenditure: 2103000 Open source
20002000-12-31	Free cash flow margin	-15.4%	Revenue: 30028000 Open source Operating Cash Flow: -2933000 Open source Capital Expenditure: 1694000 Open source
20012001-12-10	Free cash flow margin	14.4%	Revenue: 42616000 Open source Operating Cash Flow: 8823000 Open source Capital Expenditure: 2705000 Open source
20012001-12-31	Free cash flow margin	14.4%	Revenue: 42616000 Open source Operating Cash Flow: 8823000 Open source Capital Expenditure: 2705000 Open source
20022002-12-10	Free cash flow margin	8.5%	Revenue: 95491000 Open source Operating Cash Flow: 9604000 Open source Capital Expenditure: 1494000 Open source
20022002-12-31	Free cash flow margin	8.5%	Revenue: 95491000 Open source Operating Cash Flow: 9604000 Open source Capital Expenditure: 1494000 Open source
20032003-12-10	Free cash flow margin	7.5%	Revenue: 108059000 Open source Operating Cash Flow: 10929000 Open source Capital Expenditure: 2852000 Open source
20032003-12-31	Free cash flow margin	8.7%	Revenue: 93029000 Open source Operating Cash Flow: 10929000 Open source Capital Expenditure: 2827000 Open source
20042004-12-31	Free cash flow margin	-3.7%	Revenue: 148081000 Open source Operating Cash Flow: 294000 Open source Capital Expenditure: 5752000 Open source
20052005-12-31	Free cash flow margin	3.9%	Revenue: 293726000 Open source Operating Cash Flow: 19560000 Open source Capital Expenditure: 8010000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 19.6M 2005

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
19991999-12-31	Operating cash flow	951000	Operating Cash Flow: 951000 Open source
20002000-12-31	Operating cash flow	-2933000	Operating Cash Flow: -2933000 Open source
20012001-12-10	Operating cash flow	8823000	Operating Cash Flow: 8823000 Open source
20012001-12-31	Operating cash flow	8823000	Operating Cash Flow: 8823000 Open source
20022002-12-10	Operating cash flow	9604000	Operating Cash Flow: 9604000 Open source
20022002-12-31	Operating cash flow	9604000	Operating Cash Flow: 9604000 Open source
20032003-12-10	Operating cash flow	10929000	Operating Cash Flow: 10929000 Open source
20032003-12-31	Operating cash flow	10929000	Operating Cash Flow: 10929000 Open source
20042004-12-31	Operating cash flow	294000	Operating Cash Flow: 294000 Open source
20052005-12-31	Operating cash flow	19560000	Operating Cash Flow: 19560000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 11.6M 2005

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
19991999-12-31	Free cash flow	-1152000	Operating Cash Flow: 951000 Open source Capital Expenditure: 2103000 Open source
20002000-12-31	Free cash flow	-4627000	Operating Cash Flow: -2933000 Open source Capital Expenditure: 1694000 Open source
20012001-12-10	Free cash flow	6118000	Operating Cash Flow: 8823000 Open source Capital Expenditure: 2705000 Open source
20012001-12-31	Free cash flow	6118000	Operating Cash Flow: 8823000 Open source Capital Expenditure: 2705000 Open source
20022002-12-10	Free cash flow	8110000	Operating Cash Flow: 9604000 Open source Capital Expenditure: 1494000 Open source
20022002-12-31	Free cash flow	8110000	Operating Cash Flow: 9604000 Open source Capital Expenditure: 1494000 Open source
20032003-12-10	Free cash flow	8077000	Operating Cash Flow: 10929000 Open source Capital Expenditure: 2852000 Open source
20032003-12-31	Free cash flow	8102000	Operating Cash Flow: 10929000 Open source Capital Expenditure: 2827000 Open source
20042004-12-31	Free cash flow	-5458000	Operating Cash Flow: 294000 Open source Capital Expenditure: 5752000 Open source
20052005-12-31	Free cash flow	11550000	Operating Cash Flow: 19560000 Open source Capital Expenditure: 8010000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

69.6% 2005

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
19991999-12-31	Liabilities / assets	42.9%	Total Liabilities: 15841000 Open source Total Assets: 36915000 Open source
20002000-12-31	Liabilities / assets	53.7%	Total Liabilities: 20674000 Open source Total Assets: 38494000 Open source
2001-12-10	Liabilities / assets	Not reported	No source recorded
20012001-12-31	Liabilities / assets	37.7%	Total Liabilities: 19485000 Open source Total Assets: 51662000 Open source
2002-12-10	Liabilities / assets	Not reported	No source recorded
20022002-12-31	Liabilities / assets	56.2%	Total Liabilities: 52726000 Open source Total Assets: 93755000 Open source
20032003-12-10	Liabilities / assets	17.1%	Total Liabilities: 23271000 Open source Total Assets: 136380000 Open source
20032003-12-31	Liabilities / assets	17.1%	Total Liabilities: 23271000 Open source Total Assets: 136380000 Open source
20042004-12-31	Liabilities / assets	70.8%	Total Liabilities: 391001000 Open source Total Assets: 552139000 Open source
20052005-12-31	Liabilities / assets	69.6%	Total Liabilities: 384260000 Open source Total Assets: 552037000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.06× 2005

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
19991999-12-31	Current assets / current liabilities	6.45×	Current Assets: 24474000 Open source Current Liabilities: 3794000 Open source
20002000-12-31	Current assets / current liabilities	4.26×	Current Assets: 27241000 Open source Current Liabilities: 6391000 Open source
2001-12-10	Current assets / current liabilities	Not reported	No source recorded
20012001-12-31	Current assets / current liabilities	2.36×	Current Assets: 37928000 Open source Current Liabilities: 16067000 Open source
2002-12-10	Current assets / current liabilities	Not reported	No source recorded
20022002-12-31	Current assets / current liabilities	3.46×	Current Assets: 46287000 Open source Current Liabilities: 13380000 Open source
20032003-12-10	Current assets / current liabilities	7.36×	Current Assets: 91855000 Open source Current Liabilities: 12488000 Open source
20032003-12-31	Current assets / current liabilities	7.36×	Current Assets: 91855000 Open source Current Liabilities: 12488000 Open source
20042004-12-31	Current assets / current liabilities	2.94×	Current Assets: 140782000 Open source Current Liabilities: 47916000 Open source
20052005-12-31	Current assets / current liabilities	3.06×	Current Assets: 141607000 Open source Current Liabilities: 46343000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
1999 1999-01-01 – 1999-12-31	USD 1.62 million Exact value Exact value: 1619000 USD 1999-01-01 – 1999-12-31: 1619000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ReAble Therapeutics, Inc. · 1999-12-31 ReAble Therapeutics, Inc. (edgar:944763) Net Income: 1619000 USD Concept: fundies:NetIncome Period: 1999-01-01 to 1999-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ANetIncome&period=1999-12-31&surface=latest&period_type=duration&start=1999-01-01&unit=USD&dimensions= Input fundies:NetIncome: 1619000 USD (1999-01-01 to 1999-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-02-000963.txt#2349 The citation records this snapshot. The page link may show a newer release later.	USD 951,000 Exact value Exact value: 951000 USD 1999-01-01 – 1999-12-31: 951000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ReAble Therapeutics, Inc. · 1999-12-31 ReAble Therapeutics, Inc. (edgar:944763) Operating Cash Flow: 951000 USD Concept: fundies:OperatingCashFlow Period: 1999-01-01 to 1999-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3AOperatingCashFlow&period=1999-12-31&surface=latest&period_type=duration&start=1999-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 951000 USD (1999-01-01 to 1999-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-02-000963.txt#2365 The citation records this snapshot. The page link may show a newer release later.	USD 2.1 million Exact value Exact value: 2103000 USD 1999-01-01 – 1999-12-31: 2103000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ReAble Therapeutics, Inc. · 1999-12-31 ReAble Therapeutics, Inc. (edgar:944763) Capital Expenditure: 2103000 USD Concept: fundies:CapitalExpenditure Period: 1999-01-01 to 1999-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ACapitalExpenditure&period=1999-12-31&surface=latest&period_type=duration&start=1999-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2103000 USD (1999-01-01 to 1999-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-02-000963.txt#2371 The citation records this snapshot. The page link may show a newer release later.	−USD 1.15 million Calculation and evidence 951000 − 2103000 USD Exact free cash flow: -1152000 USD 1999-01-01 – 1999-12-31: 951000 USD · Inspect Operating Cash Flow · Source 1999-01-01 – 1999-12-31: 2103000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ReAble Therapeutics, Inc. · 1999-12-31 ReAble Therapeutics, Inc. (edgar:944763) Free cash flow: -1152000 USD Concept: free-cash-flow Period: 1999-01-01 to 1999-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 951000 USD (1999-01-01 to 1999-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-02-000963.txt#2365 Input fundies:CapitalExpenditure: 2103000 USD (1999-01-01 to 1999-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-02-000963.txt#2371 The citation records this snapshot. The page link may show a newer release later.
2000 2000-01-01 – 2000-12-31	−USD 3.26 million Exact value Exact value: -3263000 USD 2000-01-01 – 2000-12-31: -3263000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ReAble Therapeutics, Inc. · 2000-12-31 ReAble Therapeutics, Inc. (edgar:944763) Net Income: -3263000 USD Concept: fundies:NetIncome Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ANetIncome&period=2000-12-31&surface=latest&period_type=duration&start=2000-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3263000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-03-001277.txt#4801 The citation records this snapshot. The page link may show a newer release later.	−USD 2.93 million Exact value Exact value: -2933000 USD 2000-01-01 – 2000-12-31: -2933000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ReAble Therapeutics, Inc. · 2000-12-31 ReAble Therapeutics, Inc. (edgar:944763) Operating Cash Flow: -2933000 USD Concept: fundies:OperatingCashFlow Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3AOperatingCashFlow&period=2000-12-31&surface=latest&period_type=duration&start=2000-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2933000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-03-001277.txt#5054 The citation records this snapshot. The page link may show a newer release later.	USD 1.69 million Exact value Exact value: 1694000 USD 2000-01-01 – 2000-12-31: 1694000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ReAble Therapeutics, Inc. · 2000-12-31 ReAble Therapeutics, Inc. (edgar:944763) Capital Expenditure: 1694000 USD Concept: fundies:CapitalExpenditure Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ACapitalExpenditure&period=2000-12-31&surface=latest&period_type=duration&start=2000-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1694000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-03-001277.txt#5124 The citation records this snapshot. The page link may show a newer release later.	−USD 4.63 million Calculation and evidence -2933000 − 1694000 USD Exact free cash flow: -4627000 USD 2000-01-01 – 2000-12-31: -2933000 USD · Inspect Operating Cash Flow · Source 2000-01-01 – 2000-12-31: 1694000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ReAble Therapeutics, Inc. · 2000-12-31 ReAble Therapeutics, Inc. (edgar:944763) Free cash flow: -4627000 USD Concept: free-cash-flow Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2933000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-03-001277.txt#5054 Input fundies:CapitalExpenditure: 1694000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-03-001277.txt#5124 The citation records this snapshot. The page link may show a newer release later.
2001 2000-12-11 – 2001-12-10	USD 548,000 Exact value Exact value: 548000 USD 2000-12-11 – 2001-12-10: 548000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ReAble Therapeutics, Inc. · 2001-12-10 ReAble Therapeutics, Inc. (edgar:944763) Net Income: 548000 USD Concept: fundies:NetIncome Period: 2000-12-11 to 2001-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ANetIncome&period=2001-12-10&surface=latest&period_type=duration&start=2000-12-11&unit=USD&dimensions= Input fundies:NetIncome: 548000 USD (2000-12-11 to 2001-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#5914 The citation records this snapshot. The page link may show a newer release later.	USD 8.82 million Exact value Exact value: 8823000 USD 2000-12-11 – 2001-12-10: 8823000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ReAble Therapeutics, Inc. · 2001-12-10 ReAble Therapeutics, Inc. (edgar:944763) Operating Cash Flow: 8823000 USD Concept: fundies:OperatingCashFlow Period: 2000-12-11 to 2001-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3AOperatingCashFlow&period=2001-12-10&surface=latest&period_type=duration&start=2000-12-11&unit=USD&dimensions= Input fundies:OperatingCashFlow: 8823000 USD (2000-12-11 to 2001-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6050 The citation records this snapshot. The page link may show a newer release later.	USD 2.71 million Exact value Exact value: 2705000 USD 2000-12-11 – 2001-12-10: 2705000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ReAble Therapeutics, Inc. · 2001-12-10 ReAble Therapeutics, Inc. (edgar:944763) Capital Expenditure: 2705000 USD Concept: fundies:CapitalExpenditure Period: 2000-12-11 to 2001-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ACapitalExpenditure&period=2001-12-10&surface=latest&period_type=duration&start=2000-12-11&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2705000 USD (2000-12-11 to 2001-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6090 The citation records this snapshot. The page link may show a newer release later.	USD 6.12 million Calculation and evidence 8823000 − 2705000 USD Exact free cash flow: 6118000 USD 2000-12-11 – 2001-12-10: 8823000 USD · Inspect Operating Cash Flow · Source 2000-12-11 – 2001-12-10: 2705000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ReAble Therapeutics, Inc. · 2001-12-10 ReAble Therapeutics, Inc. (edgar:944763) Free cash flow: 6118000 USD Concept: free-cash-flow Period: 2000-12-11 to 2001-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8823000 USD (2000-12-11 to 2001-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6050 Input fundies:CapitalExpenditure: 2705000 USD (2000-12-11 to 2001-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6090 The citation records this snapshot. The page link may show a newer release later.
2001 2001-01-01 – 2001-12-31	USD 548,000 Exact value Exact value: 548000 USD 2001-01-01 – 2001-12-31: 548000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ReAble Therapeutics, Inc. · 2001-12-31 ReAble Therapeutics, Inc. (edgar:944763) Net Income: 548000 USD Concept: fundies:NetIncome Period: 2001-01-01 to 2001-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ANetIncome&period=2001-12-31&surface=latest&period_type=duration&start=2001-01-01&unit=USD&dimensions= Input fundies:NetIncome: 548000 USD (2001-01-01 to 2001-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-03-001277.txt#4801 The citation records this snapshot. The page link may show a newer release later.	USD 8.82 million Exact value Exact value: 8823000 USD 2001-01-01 – 2001-12-31: 8823000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ReAble Therapeutics, Inc. · 2001-12-31 ReAble Therapeutics, Inc. (edgar:944763) Operating Cash Flow: 8823000 USD Concept: fundies:OperatingCashFlow Period: 2001-01-01 to 2001-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3AOperatingCashFlow&period=2001-12-31&surface=latest&period_type=duration&start=2001-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 8823000 USD (2001-01-01 to 2001-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-03-001277.txt#5054 The citation records this snapshot. The page link may show a newer release later.	USD 2.71 million Exact value Exact value: 2705000 USD 2001-01-01 – 2001-12-31: 2705000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ReAble Therapeutics, Inc. · 2001-12-31 ReAble Therapeutics, Inc. (edgar:944763) Capital Expenditure: 2705000 USD Concept: fundies:CapitalExpenditure Period: 2001-01-01 to 2001-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ACapitalExpenditure&period=2001-12-31&surface=latest&period_type=duration&start=2001-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2705000 USD (2001-01-01 to 2001-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-03-001277.txt#5124 The citation records this snapshot. The page link may show a newer release later.	USD 6.12 million Calculation and evidence 8823000 − 2705000 USD Exact free cash flow: 6118000 USD 2001-01-01 – 2001-12-31: 8823000 USD · Inspect Operating Cash Flow · Source 2001-01-01 – 2001-12-31: 2705000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ReAble Therapeutics, Inc. · 2001-12-31 ReAble Therapeutics, Inc. (edgar:944763) Free cash flow: 6118000 USD Concept: free-cash-flow Period: 2001-01-01 to 2001-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8823000 USD (2001-01-01 to 2001-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-03-001277.txt#5054 Input fundies:CapitalExpenditure: 2705000 USD (2001-01-01 to 2001-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000930661-03-001277.txt#5124 The citation records this snapshot. The page link may show a newer release later.
2002 2001-12-11 – 2002-12-10	USD 6,000 Exact value Exact value: 6000 USD 2001-12-11 – 2002-12-10: 6000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ReAble Therapeutics, Inc. · 2002-12-10 ReAble Therapeutics, Inc. (edgar:944763) Net Income: 6000 USD Concept: fundies:NetIncome Period: 2001-12-11 to 2002-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ANetIncome&period=2002-12-10&surface=latest&period_type=duration&start=2001-12-11&unit=USD&dimensions= Input fundies:NetIncome: 6000 USD (2001-12-11 to 2002-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#5914 The citation records this snapshot. The page link may show a newer release later.	USD 9.6 million Exact value Exact value: 9604000 USD 2001-12-11 – 2002-12-10: 9604000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ReAble Therapeutics, Inc. · 2002-12-10 ReAble Therapeutics, Inc. (edgar:944763) Operating Cash Flow: 9604000 USD Concept: fundies:OperatingCashFlow Period: 2001-12-11 to 2002-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3AOperatingCashFlow&period=2002-12-10&surface=latest&period_type=duration&start=2001-12-11&unit=USD&dimensions= Input fundies:OperatingCashFlow: 9604000 USD (2001-12-11 to 2002-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6050 The citation records this snapshot. The page link may show a newer release later.	USD 1.49 million Exact value Exact value: 1494000 USD 2001-12-11 – 2002-12-10: 1494000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ReAble Therapeutics, Inc. · 2002-12-10 ReAble Therapeutics, Inc. (edgar:944763) Capital Expenditure: 1494000 USD Concept: fundies:CapitalExpenditure Period: 2001-12-11 to 2002-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ACapitalExpenditure&period=2002-12-10&surface=latest&period_type=duration&start=2001-12-11&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1494000 USD (2001-12-11 to 2002-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6090 The citation records this snapshot. The page link may show a newer release later.	USD 8.11 million Calculation and evidence 9604000 − 1494000 USD Exact free cash flow: 8110000 USD 2001-12-11 – 2002-12-10: 9604000 USD · Inspect Operating Cash Flow · Source 2001-12-11 – 2002-12-10: 1494000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ReAble Therapeutics, Inc. · 2002-12-10 ReAble Therapeutics, Inc. (edgar:944763) Free cash flow: 8110000 USD Concept: free-cash-flow Period: 2001-12-11 to 2002-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 9604000 USD (2001-12-11 to 2002-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6050 Input fundies:CapitalExpenditure: 1494000 USD (2001-12-11 to 2002-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6090 The citation records this snapshot. The page link may show a newer release later.
2002 2002-01-01 – 2002-12-31	USD 6,000 Exact value Exact value: 6000 USD 2002-01-01 – 2002-12-31: 6000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ReAble Therapeutics, Inc. · 2002-12-31 ReAble Therapeutics, Inc. (edgar:944763) Net Income: 6000 USD Concept: fundies:NetIncome Period: 2002-01-01 to 2002-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ANetIncome&period=2002-12-31&surface=latest&period_type=duration&start=2002-01-01&unit=USD&dimensions= Input fundies:NetIncome: 6000 USD (2002-01-01 to 2002-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-05-005243.txt#12593 The citation records this snapshot. The page link may show a newer release later.	USD 9.6 million Exact value Exact value: 9604000 USD 2002-01-01 – 2002-12-31: 9604000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ReAble Therapeutics, Inc. · 2002-12-31 ReAble Therapeutics, Inc. (edgar:944763) Operating Cash Flow: 9604000 USD Concept: fundies:OperatingCashFlow Period: 2002-01-01 to 2002-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3AOperatingCashFlow&period=2002-12-31&surface=latest&period_type=duration&start=2002-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 9604000 USD (2002-01-01 to 2002-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-05-005243.txt#12876 The citation records this snapshot. The page link may show a newer release later.	USD 1.49 million Exact value Exact value: 1494000 USD 2002-01-01 – 2002-12-31: 1494000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ReAble Therapeutics, Inc. · 2002-12-31 ReAble Therapeutics, Inc. (edgar:944763) Capital Expenditure: 1494000 USD Concept: fundies:CapitalExpenditure Period: 2002-01-01 to 2002-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ACapitalExpenditure&period=2002-12-31&surface=latest&period_type=duration&start=2002-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1494000 USD (2002-01-01 to 2002-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-05-005243.txt#12936 The citation records this snapshot. The page link may show a newer release later.	USD 8.11 million Calculation and evidence 9604000 − 1494000 USD Exact free cash flow: 8110000 USD 2002-01-01 – 2002-12-31: 9604000 USD · Inspect Operating Cash Flow · Source 2002-01-01 – 2002-12-31: 1494000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ReAble Therapeutics, Inc. · 2002-12-31 ReAble Therapeutics, Inc. (edgar:944763) Free cash flow: 8110000 USD Concept: free-cash-flow Period: 2002-01-01 to 2002-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 9604000 USD (2002-01-01 to 2002-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-05-005243.txt#12876 Input fundies:CapitalExpenditure: 1494000 USD (2002-01-01 to 2002-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-05-005243.txt#12936 The citation records this snapshot. The page link may show a newer release later.
2003 2002-12-11 – 2003-12-10	−USD 2.52 million Exact value Exact value: -2517000 USD 2002-12-11 – 2003-12-10: -2517000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ReAble Therapeutics, Inc. · 2003-12-10 ReAble Therapeutics, Inc. (edgar:944763) Net Income: -2517000 USD Concept: fundies:NetIncome Period: 2002-12-11 to 2003-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ANetIncome&period=2003-12-10&surface=latest&period_type=duration&start=2002-12-11&unit=USD&dimensions= Input fundies:NetIncome: -2517000 USD (2002-12-11 to 2003-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#5914 The citation records this snapshot. The page link may show a newer release later.	USD 10.93 million Exact value Exact value: 10929000 USD 2002-12-11 – 2003-12-10: 10929000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ReAble Therapeutics, Inc. · 2003-12-10 ReAble Therapeutics, Inc. (edgar:944763) Operating Cash Flow: 10929000 USD Concept: fundies:OperatingCashFlow Period: 2002-12-11 to 2003-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3AOperatingCashFlow&period=2003-12-10&surface=latest&period_type=duration&start=2002-12-11&unit=USD&dimensions= Input fundies:OperatingCashFlow: 10929000 USD (2002-12-11 to 2003-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6050 The citation records this snapshot. The page link may show a newer release later.	USD 2.85 million Exact value Exact value: 2852000 USD 2002-12-11 – 2003-12-10: 2852000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ReAble Therapeutics, Inc. · 2003-12-10 ReAble Therapeutics, Inc. (edgar:944763) Capital Expenditure: 2852000 USD Concept: fundies:CapitalExpenditure Period: 2002-12-11 to 2003-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ACapitalExpenditure&period=2003-12-10&surface=latest&period_type=duration&start=2002-12-11&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2852000 USD (2002-12-11 to 2003-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6090 The citation records this snapshot. The page link may show a newer release later.	USD 8.08 million Calculation and evidence 10929000 − 2852000 USD Exact free cash flow: 8077000 USD 2002-12-11 – 2003-12-10: 10929000 USD · Inspect Operating Cash Flow · Source 2002-12-11 – 2003-12-10: 2852000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ReAble Therapeutics, Inc. · 2003-12-10 ReAble Therapeutics, Inc. (edgar:944763) Free cash flow: 8077000 USD Concept: free-cash-flow Period: 2002-12-11 to 2003-12-10 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 10929000 USD (2002-12-11 to 2003-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6050 Input fundies:CapitalExpenditure: 2852000 USD (2002-12-11 to 2003-12-10) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000944763-04-000002.txt#6090 The citation records this snapshot. The page link may show a newer release later.
2003 2003-01-01 – 2003-12-31	−USD 2.52 million Exact value Exact value: -2517000 USD 2003-01-01 – 2003-12-31: -2517000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ReAble Therapeutics, Inc. · 2003-12-31 ReAble Therapeutics, Inc. (edgar:944763) Net Income: -2517000 USD Concept: fundies:NetIncome Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ANetIncome&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2517000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12102 The citation records this snapshot. The page link may show a newer release later.	USD 10.93 million Exact value Exact value: 10929000 USD 2003-01-01 – 2003-12-31: 10929000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ReAble Therapeutics, Inc. · 2003-12-31 ReAble Therapeutics, Inc. (edgar:944763) Operating Cash Flow: 10929000 USD Concept: fundies:OperatingCashFlow Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3AOperatingCashFlow&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 10929000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12414 The citation records this snapshot. The page link may show a newer release later.	USD 2.83 million Exact value Exact value: 2827000 USD 2003-01-01 – 2003-12-31: 2827000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ReAble Therapeutics, Inc. · 2003-12-31 ReAble Therapeutics, Inc. (edgar:944763) Capital Expenditure: 2827000 USD Concept: fundies:CapitalExpenditure Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ACapitalExpenditure&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2827000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12489 The citation records this snapshot. The page link may show a newer release later.	USD 8.1 million Calculation and evidence 10929000 − 2827000 USD Exact free cash flow: 8102000 USD 2003-01-01 – 2003-12-31: 10929000 USD · Inspect Operating Cash Flow · Source 2003-01-01 – 2003-12-31: 2827000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ReAble Therapeutics, Inc. · 2003-12-31 ReAble Therapeutics, Inc. (edgar:944763) Free cash flow: 8102000 USD Concept: free-cash-flow Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 10929000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12414 Input fundies:CapitalExpenditure: 2827000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12489 The citation records this snapshot. The page link may show a newer release later.
2004 2004-01-01 – 2004-12-31	USD 5.53 million Exact value Exact value: 5527000 USD 2004-01-01 – 2004-12-31: 5527000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ReAble Therapeutics, Inc. · 2004-12-31 ReAble Therapeutics, Inc. (edgar:944763) Net Income: 5527000 USD Concept: fundies:NetIncome Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ANetIncome&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:NetIncome: 5527000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12102 The citation records this snapshot. The page link may show a newer release later.	USD 294,000 Exact value Exact value: 294000 USD 2004-01-01 – 2004-12-31: 294000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ReAble Therapeutics, Inc. · 2004-12-31 ReAble Therapeutics, Inc. (edgar:944763) Operating Cash Flow: 294000 USD Concept: fundies:OperatingCashFlow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3AOperatingCashFlow&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 294000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12414 The citation records this snapshot. The page link may show a newer release later.	USD 5.75 million Exact value Exact value: 5752000 USD 2004-01-01 – 2004-12-31: 5752000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ReAble Therapeutics, Inc. · 2004-12-31 ReAble Therapeutics, Inc. (edgar:944763) Capital Expenditure: 5752000 USD Concept: fundies:CapitalExpenditure Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ACapitalExpenditure&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5752000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12489 The citation records this snapshot. The page link may show a newer release later.	−USD 5.46 million Calculation and evidence 294000 − 5752000 USD Exact free cash flow: -5458000 USD 2004-01-01 – 2004-12-31: 294000 USD · Inspect Operating Cash Flow · Source 2004-01-01 – 2004-12-31: 5752000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ReAble Therapeutics, Inc. · 2004-12-31 ReAble Therapeutics, Inc. (edgar:944763) Free cash flow: -5458000 USD Concept: free-cash-flow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 294000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12414 Input fundies:CapitalExpenditure: 5752000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12489 The citation records this snapshot. The page link may show a newer release later.
2005 2005-01-01 – 2005-12-31	USD 12.33 million Exact value Exact value: 12330000 USD 2005-01-01 – 2005-12-31: 12330000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ReAble Therapeutics, Inc. · 2005-12-31 ReAble Therapeutics, Inc. (edgar:944763) Net Income: 12330000 USD Concept: fundies:NetIncome Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ANetIncome&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:NetIncome: 12330000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12102 The citation records this snapshot. The page link may show a newer release later.	USD 19.56 million Exact value Exact value: 19560000 USD 2005-01-01 – 2005-12-31: 19560000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ReAble Therapeutics, Inc. · 2005-12-31 ReAble Therapeutics, Inc. (edgar:944763) Operating Cash Flow: 19560000 USD Concept: fundies:OperatingCashFlow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3AOperatingCashFlow&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 19560000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12414 The citation records this snapshot. The page link may show a newer release later.	USD 8.01 million Exact value Exact value: 8010000 USD 2005-01-01 – 2005-12-31: 8010000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ReAble Therapeutics, Inc. · 2005-12-31 ReAble Therapeutics, Inc. (edgar:944763) Capital Expenditure: 8010000 USD Concept: fundies:CapitalExpenditure Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763/explain?concept=fundies%3ACapitalExpenditure&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8010000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12489 The citation records this snapshot. The page link may show a newer release later.	USD 11.55 million Calculation and evidence 19560000 − 8010000 USD Exact free cash flow: 11550000 USD 2005-01-01 – 2005-12-31: 19560000 USD · Inspect Operating Cash Flow · Source 2005-01-01 – 2005-12-31: 8010000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ReAble Therapeutics, Inc. · 2005-12-31 ReAble Therapeutics, Inc. (edgar:944763) Free cash flow: 11550000 USD Concept: free-cash-flow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T13:39:14Z Snapshot: f40034e5d78640e5016379d0cc84baba78ee2698c76ab4790a7ff23d125f80e1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944763?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 19560000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12414 Input fundies:CapitalExpenditure: 8010000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944763/0000950134-06-005042.txt#12489 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

54 filings · 0 latest values · 0 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000944763, 944763, edgar:944763

Also known as ENCORE MEDICAL CORP, HEALTHCARE ACQUISITION CORP

ReAble Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2005 2005-01-01 – 2005-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation